| Size | Price | Stock | Qty |
|---|---|---|---|
| 1mg |
|
||
| 2mg |
|
||
| 5mg |
|
||
| 10mg | |||
| Other Sizes |
| Targets |
H+/K+-ATPase (Proton Pump). Lansoprazole D4 is a substituted benzimidazole that acts as an irreversible (covalent) inhibitor of the gastric proton pump (H+/K+-ATPase) located on the luminal surface of gastric parietal cells. It binds covalently to cysteine residues on the enzyme's alpha-subunit, inhibiting the final step of gastric acid secretion (exchange of H+ and K+ ions), leading to complete and prolonged suppression of acid output regardless of the stimulus (histamine, acetylcholine, gastrin).
|
|---|---|
| ln Vitro |
Lansoprazole (unlabeled) inhibits H+/K+-ATPase activity in gastric microsomes in a concentration-dependent manner with an IC50 of approximately 6.3-7 microM for H+ and K+ accumulation, respectively. It inhibits H+/K+-ATPase activity by approximately 60% when used at a concentration of 10 microM in enzyme assays. The D4-labeled analog is used as an internal standard and is not assessed for activity in vitro; its binding affinity is assumed to be identical to that of the parent compound.
|
| ln Vivo |
Lansoprazole (1-100 mg/kg orally) produces dose-dependent inhibition of gastric acid secretion in pylorus-ligated rats (Shay rat model), with an ED50 for acid output of approximately 3-10 mg/kg. It increases intragastric pH and provides rapid healing of gastric and duodenal ulcers in chronic animal models. In Helicobacter pylori-infected animal models, lansoprazole (with antibiotics) reduces bacterial load and improves cure rates by altering the gastric environment. The D4 version is the internal standard for these studies.
|
| Enzyme Assay |
Not applicable (not an enzyme assay compound; it is an analytical internal standard). The parent drug lansoprazole is a prodrug that is activated by acid. Cell-free H+/K+-ATPase inhibition is measured by preparing gastric microsomes (vesicles) from hog or rabbit stomach. The microsomal preparation (20-50 microg protein) is incubated with varying concentrations of lansoprazole (0.1-100 microM) in a reaction mixture containing 20 mM PIPES/Tris buffer pH 7.0, 2 mM MgCl2, and 2 mM ATP for 30 minutes at 37degC. H+/K+-ATPase activity is measured by K+-dependent ATP hydrolysis: the amount of inorganic phosphate (Pi) released from ATP is measured colorimetrically (malachite green assay). IC50 values are calculated.
|
| Cell Assay |
Not applicable (no direct cellular assays for the internal standard). The parent drug lansoprazole is evaluated in isolated rabbit or rat gastric glands. Glands are incubated with buffer containing [14C]-aminopyrine (a weak base used as a marker for acid accumulation) and varying concentrations of lansoprazole (0.1-100 microM) with or without stimulation with histamine (10-⁵ M) or dibutyryl cAMP. After 30-60 minutes, the glands are separated by filtration, and the ratio of [14C]-aminopyrine accumulation in the glands vs. medium is calculated as a measure of acid production. The IC50 for inhibition of stimulated acid accumulation is calculated.
|
| Animal Protocol |
Male Sprague-Dawley rats (200-250 g, fasted for 24 h) are used for the pylorus-ligation method. Under isoflurane anesthesia, the abdomen is incised, and the pylorus is ligated. Lansoprazole (3-100 mg/kg) or vehicle is administered orally or intraduodenally immediately after ligation. After 4-6 hours, animals are euthanized, and the gastric contents are collected by lavage. The volume of gastric juice is measured, and the total acid output (TAO) is determined by titration of the gastric contents with 0.01 N NaOH to pH 7.0. The ED50 (dose producing 50% inhibition of acid secretion) is calculated. Blood samples are collected for LC-MS/MS analysis of lansoprazole and its metabolites using Lansoprazole D4 as the internal standard.
|
| ADME/Pharmacokinetics |
Lansoprazole D4 serves as an internal standard for LC-MS/MS quantification. The parent drug lansoprazole is administered as an enteric-coated formulation to prevent gastric acid degradation. It is well absorbed (oral bioavailability ~80-90%), highly protein bound (>95%), and has a terminal half-life of approximately 1-2 hours in humans. It is extensively metabolized in the liver by CYP3A4 and CYP2C19 to its inactive sulfone and 5-hydroxy metabolites. The labeled version has nearly identical physicochemical properties for accurate bioanalysis.
|
| Toxicity/Toxicokinetics |
The D4-labeled version is for research use only and not for human consumption. The parent drug lansoprazole is generally well tolerated. Common adverse effects include headache, diarrhea, constipation, nausea, and abdominal pain. Long-term use may increase the risk of vitamin B12 deficiency, hypomagnesemia, Clostridium difficile-associated diarrhea, and bone fractures (hip, wrist, spine). Rare but serious events include acute interstitial nephritis (AIN) and lupus erythematosus.
|
| References | |
| Additional Infomation |
Lansoprazole (Prevacid®) was FDA-approved in 1995 for the treatment of duodenal ulcers, gastric ulcers, gastroesophageal reflux disease (GERD), erosive esophagitis, and as part of a combination therapy for H. pylori eradication. Lansoprazole D4 is a research internal standard used in LC-MS/MS bioanalysis to support pharmacokinetic studies, bioequivalence trials, and drug-drug interaction assessments (particularly with CYP2C19 and CYP3A4). It is also used in forensic toxicology and clinical drug monitoring.
|
| Molecular Formula |
C16H10D4F3N3O2S
|
|---|---|
| Molecular Weight |
373.3861
|
| Exact Mass |
369.076
|
| CAS # |
934294-22-1
|
| Related CAS # |
Lansoprazole;103577-45-3;(S)-Lansoprazole;138530-95-7
|
| PubChem CID |
45039648
|
| Appearance |
Off-white to light yellow solid powder
|
| LogP |
4.38
|
| Hydrogen Bond Donor Count |
1
|
| Hydrogen Bond Acceptor Count |
8
|
| Rotatable Bond Count |
5
|
| Heavy Atom Count |
25
|
| Complexity |
480
|
| Defined Atom Stereocenter Count |
0
|
| SMILES |
[2H]C1=C(C(=C2C(=C1[2H])NC(=N2)S(=O)CC3=NC=CC(=C3C)OCC(F)(F)F)[2H])[2H]
|
| InChi Key |
MJIHNNLFOKEZEW-QFFDRWTDSA-N
|
| InChi Code |
InChI=1S/C16H14F3N3O2S/c1-10-13(20-7-6-14(10)24-9-16(17,18)19)8-25(23)15-21-11-4-2-3-5-12(11)22-15/h2-7H,8-9H2,1H3,(H,21,22)/i2D,3D,4D,5D
|
| Chemical Name |
4,5,6,7-tetradeuterio-2-[[3-methyl-4-(2,2,2-trifluoroethoxy)pyridin-2-yl]methylsulfinyl]-1H-benzimidazole
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
May dissolve in DMSO (in most cases), if not, try other solvents such as H2O, Ethanol, or DMF with a minute amount of products to avoid loss of samples
|
|---|---|
| Solubility (In Vivo) |
Note: Listed below are some common formulations that may be used to formulate products with low water solubility (e.g. < 1 mg/mL), you may test these formulations using a minute amount of products to avoid loss of samples.
Injection Formulations
Injection Formulation 1: DMSO : Tween 80： Saline = 10 : 5 : 85 (i.e. 100 μL DMSO stock solution → 50 μL Tween 80 → 850 μL Saline)(e.g. IP/IV/IM/SC) *Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH ₂ O to obtain a clear solution. Injection Formulation 2: DMSO : PEG300 ：Tween 80 : Saline = 10 : 40 : 5 : 45 (i.e. 100 μL DMSO → 400 μLPEG300 → 50 μL Tween 80 → 450 μL Saline) Injection Formulation 3: DMSO : Corn oil = 10 : 90 (i.e. 100 μL DMSO → 900 μL Corn oil) Example: Take the Injection Formulation 3 (DMSO : Corn oil = 10 : 90) as an example, if 1 mL of 2.5 mg/mL working solution is to be prepared, you can take 100 μL 25 mg/mL DMSO stock solution and add to 900 μL corn oil, mix well to obtain a clear or suspension solution (2.5 mg/mL, ready for use in animals). View More
Injection Formulation 4: DMSO : 20% SBE-β-CD in saline = 10 : 90 [i.e. 100 μL DMSO → 900 μL (20% SBE-β-CD in saline)] Oral Formulations
Oral Formulation 1: Suspend in 0.5% CMC Na (carboxymethylcellulose sodium) Oral Formulation 2: Suspend in 0.5% Carboxymethyl cellulose Example: Take the Oral Formulation 1 (Suspend in 0.5% CMC Na) as an example, if 100 mL of 2.5 mg/mL working solution is to be prepared, you can first prepare 0.5% CMC Na solution by measuring 0.5 g CMC Na and dissolve it in 100 mL ddH2O to obtain a clear solution; then add 250 mg of the product to 100 mL 0.5% CMC Na solution, to make the suspension solution (2.5 mg/mL, ready for use in animals). View More
Oral Formulation 3: Dissolved in PEG400 (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 2.6782 mL | 13.3908 mL | 26.7816 mL | |
| 5 mM | 0.5356 mL | 2.6782 mL | 5.3563 mL | |
| 10 mM | 0.2678 mL | 1.3391 mL | 2.6782 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
